← Leaderboards
Andre S Bachmann
Michigan State University
$2,358,851
Attributed
$3,732,214
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $731.2K · FY2006–25$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,732,214 · 4
By mechanism
R01$3,263,924 · 2
R21$453,290 · 1
R13$15,000 · 1
Top collaborators
- Caleb Bupp3 shared
- Robert A Casero3 shared
Most similar at Michigan State University
Same institution · by research overlap
- Caleb Bupp$686,681
- Robert A Casero$11,306,418
- Youssef A Kousa$888,375
Others in their field
Top investigators on “Polyamines”
- Keith T Wilson · Vanderbilt University Medical Center$16,707,774
- Margaret A. Phillips · Ut Southwestern Medical Center$14,757,733
- Jian-Ying Wang · Baltimore Va Medical Center$12,778,699
- Shelly Chi-Loo Lu · Cedars-Sinai Medical Center$11,685,452
- Robert A Casero · Michigan State University$11,174,804
- Colin G Nichols · Washington University$9,979,309
Research focus
PolyaminesCellsDl-Alpha-DifluoromethylornithineEnzymesOrnithine DecarboxylaseCell LinePharmaceutical PreparationsIn VitroRegulationMetabolicMetabolismPathway InteractionsSpermidineSpermineNeuroblastomaMutationSeriesMolecularPutrescineAffectResponseMalignant NeoplasmsApoptosisMycn Gene
Grant awards (14)
Leveraging modulation of polyamine metabolism for therapeutic advantage in genetic disorders$671,409
R01 · FY2025 · HD · contact PI
Leveraging modulation of polyamine metabolism for therapeutic advantage in genetic disorders$672,433
R01 · FY2024 · HD · contact PI
Leveraging modulation of polyamine metabolism for therapeutic advantage in genetic disorders$716,202
R01 · FY2023 · HD · contact PI
2023 Polyamines Gordon Research Conference and Gordon Research Seminar$15,000
R13 · FY2023 · CA · contact PI
Novel ODC Inhibitor Phaseolotoxin in Neuroblastoma$259,540
R21 · FY2019 · CA · contact PI
Novel ODC Inhibitor Phaseolotoxin in Neuroblastoma$193,750
R21 · FY2018 · CA · contact PI
Role of Polyamines in MYCN-Amplified Neuroblastoma$214,682
R01 · FY2009 · CA · contact PI
Role of Polyamines in MYCN-Amplified Neuroblastoma$111,994
R01 · FY2009 · CA · contact PI
Role of Polyamines in MYCN-Amplified Neuroblastoma$77,504
R01 · FY2009 · CA · contact PI
Role of Polyamines in MYCN-Amplified Neuroblastoma$214,682
R01 · FY2008 · CA · contact PI
Role of Polyamines in MYCN-Amplified Neuroblastoma$77,504
R01 · FY2008 · CA · contact PI
Role of Polyamines in MYCN-Amplified Neuroblastoma$214,682
R01 · FY2007 · CA · contact PI
Role of Polyamines in MYCN-Amplified Neuroblastoma$71,738
R01 · FY2007 · CA · contact PI
Role of Polyamines in MYCN-Amplified Neuroblastoma$221,094
R01 · FY2006 · CA · contact PI